Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells

ABSTRACT The interaction of human immunodeficiency virus (HIV)-derived vectors with wild-type virus was analyzed in transduced cells. Vector transcripts upregulated by infection had no measurable effect on HIV type 1 (HIV-1) expression but competed efficiently for encapsidation, inhibiting the infectivity and spread of HIV-1 in culture and leading to mobilization and recombination of the vector. These effects were abrogated with a self-inactivating vector.

[1]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[2]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[3]  J. Olsen.  Gene transfer vectors derived from equine infectious anemia virus , 1998, Gene Therapy.

[4]  L. Naldini.  Lentiviruses as gene transfer agents for delivery to non-dividing cells. , 1998, Current opinion in biotechnology.

[5]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[6]  S. Arya,et al.  Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging. , 1998, Human gene therapy.

[7]  H. Gelderblom,et al.  Efficient HIV‐1 replication can occur in the absence of the viral matrix protein , 1998, The EMBO journal.

[8]  F. Wong-Staal,et al.  Anti-HIV effects of HIV vectors. , 1998, Virology.

[9]  E. Poeschla,et al.  Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors , 1998, Nature Medicine.

[10]  A. Kingsman,et al.  Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[11]  D. Peterson,et al.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors , 1997, Nature Genetics.

[12]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[13]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[14]  S. Karlsson,et al.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Poeschla,et al.  Development of HIV vectors for anti-HIV gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Redfield,et al.  Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[18]  G. Li,et al.  Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4 , 1996, Journal of virology.

[19]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[20]  S. Bartz,et al.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control , 1996, Journal of virology.

[21]  F. Bushman,et al.  HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase , 1995, Cell.

[22]  E. Gilboa,et al.  Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain , 1994, Journal of virology.

[23]  J. Hauber,et al.  Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes. , 1994, Human gene therapy.

[24]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Sullenger,et al.  Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation , 1991, Journal of virology.

[27]  Wei-Shau Hu,et al.  Retroviral recombination and reverse transcription. , 1990, Science.

[28]  J. Sodroski,et al.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants , 1990, Journal of virology.

[29]  F. Wong-Staal,et al.  Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system , 1998, Gene Therapy.

[30]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.